CompletedNot Applicable

Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

Switzerland400 participantsStarted 2024-01-12

Plain-language summary

The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Physicians will be required to meet all of the following inclusion criteria: * Must provide consent for participation * Must spend ≥50% of time in direct patient care * Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months. * Have prescribed Exjade and/or generic deferasirox within the last 12 months. Exclusion Criteria: Physicians meeting the following criterion will not be eligible to take the survey: • Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.

What they're measuring

Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC)

Timeframe: Through study completion, an average of 6 months.

Trial details

NCT IDNCT06215287

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-02-15

View on ClinicalTrials.gov More Chronic Iron Overload trials